Controlling the topology of mammalian mitochondrial DNA

Katja E. Menger, Alejandro Rodríguez-Luis, James Chapman and Thomas J. Nicholls

Wellcome Centre for Mitochondrial Research, Biosciences Institute, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
KEM, 0000-0002-6972-7326; AR-L, 0000-0003-3989-1317; JC, 0000-0002-2841-282X; TJN, 0000-0002-3034-4109

The genome of mitochondria, called mtDNA, is a small circular DNA molecule present at thousands of copies per human cell. MtDNA is packaged into nucleoprotein complexes called nucleoids, and the density of mtDNA packaging affects mitochondrial gene expression. Genetic processes such as transcription, DNA replication and DNA packaging alter DNA topology, and these topological problems are solved by a family of enzymes called topoisomerases. Within mitochondria, topoisomerases are involved firstly in the regulation of mtDNA supercoiling and secondly in disentangling interlinked mtDNA molecules following mtDNA replication. The loss of mitochondrial topoisomerase activity leads to defects in mitochondrial function, and variants in the dual-localized type IA topoisomerase TOP3A have also been reported to cause human mitochondrial disease. We review the current knowledge on processes that alter mtDNA topology, how mtDNA topology is modulated by the action of topoisomerases, and the consequences of altered mtDNA topology for mitochondrial function and human health.

1. Introduction

The mitochondria of eukaryotic cells are the product of an ancient endosymbiotic merger between an alpha-proteobacterium and a host cell [1]. While the original bacterial endosymbiont may have been expected to possess several thousand genes [2], a process of gene loss, and the transfer of genes to the nucleus, means that mitochondria are no longer functionally independent. Nevertheless, mitochondria retain a small and highly reduced vestige of the original bacterial genome, called mitochondrial DNA or mtDNA. Mitochondria are the site of a number of essential cellular processes, including oxidative phosphorylation (OXPHOS), fatty acid oxidation, and the biosynthesis of iron–sulfur clusters and haem. The majority of cellular energy, in the form of ATP, is generated via OXPHOS, which is carried out by five large multi-subunit protein complexes at the inner mitochondrial membrane (IMM). All of the protein products of mammalian mtDNA are components of the OXPHOS machinery, with mtDNA-encoded genes contributing 13 of the approximately 90 proteins that constitute the OXPHOS complexes [3]. The human mitochondrial genome is a double-stranded, circular, multicopy DNA molecule. A human cell contains between several hundred and several thousand copies of mtDNA, dispersed within the cellular mitochondrial network [4]. A loss of mtDNA function (resulting from mutations or deletions in mtDNA), or an inability to maintain a sufficient number of copies of mtDNA per cell (termed mtDNA depletion), cause a sub-group of human mitochondrial diseases. The close association between mitochondria and cellular energy production means that these disorders commonly manifest in tissues with high metabolic demand, such as the brain and muscle [5].
The current best estimate for the number of proteins that localize to mitochondria in human cells is approximately 1100 [6,7]. Aside from the 13 mtDNA-encoded genes of the OXPHOS complexes, all mitochondrially localized proteins are therefore encoded in the nucleus and must be targeted to mitochondria and post-translationally imported via a specialized import machinery [8]. The mitochondrial genome is therefore under nuclear genetic control, with an estimated 250–300 nuclear-encoded proteins being required for mtDNA expression [9].

All transactions between proteins and DNA sequences cause alterations to the topology of the DNA. As with any B-form dsDNA molecule, mtDNA adopts a right-handed double-helical structure, with the genetic information being contained at the centre of this helix. In order to replicate, repair or transcribe mtDNA, interacting proteins must manipulate the structure of the DNA molecule in order to gain access to the genetic sequence. Conversely, the packaging of mtDNA by proteins also alters the topology of mtDNA, and consequently also the accessibility of sequence elements required for transcription and replication [10]. The manipulation of DNA topology is generally considered to be essential for genome function, for example for activating transcription [11], but also creates possibilities for genome instability [12]. Mechanisms are therefore required to maintain the topological state of DNA, and a family of enzymes called topoisomerases is involved in maintaining proper DNA topology in all domains of life [13].

In the case of mtDNA, defects in either mtDNA replication or transcription manifest as the impairment of OXPHOS and mitochondrial dysfunction, which may lead to mitochondrial disease. In this review, we explore the factors that impact upon mtDNA topology, the mechanisms that regulate this topology and the consequences when these mechanisms are dysfunctional.

2. Structure and function of mitochondrial DNA

Human mtDNA is a 16 569 bp circular dsDNA molecule with genes encoded on both strands [14,15]. In addition to encoding protein products of the OXPHOS machinery, mtDNA also encodes all of the RNA molecules required for the expression of these proteins, consisting of a minimal set of 22 tRNAs and two ribosomal RNAs (figure 1a). The two strands of mtDNA are designated as the ‘heavy’ and ‘light’ strands, as their differing guanine contents confer different buoyancies during alkaline CsCl2 density gradient centrifugation [16].

Similar to its bacterial ancestors, mtDNA is highly compact and does not contain introns. Human mtDNA possesses only one major non-coding region (NCR), which contains a number of sequence elements that are required for the replication and expression of mtDNA. This includes the promoters for mitochondrial DNA transcription, termed the light-strand promoter (LSP) and the heavy-strand promoter (HSP), and the origin of replication for the heavy strand (OriH) [17]. The origin of replication for the light strand, OriL, is found within a small separate NCR within a cluster of tRNAs. The two replication origins, OriH and OriL, are sometimes thought of as dividing the mtDNA into two unequal parts, termed the major arc and the minor arc. In the NCR of a proportion of mtDNA molecules, a 650 nt piece of single-stranded DNA is stably incorporated to form a D-loop structure [18,19]. The proportion of mtDNA molecules containing a D-loop has been found to range from around 10% to around 90%, depending upon the cell or tissue type analysed [18,20–25]. The additional linear strand of the D-loop is called 7S DNA and spans the region between multiple sites close to OriH (at the 5’ end of 7S DNA) and the termination-associated sequence (TAS) close to the gene for mt-tRNAPro (at the 3’ end of 7S DNA) [26]. The fact that the 5’ ends of 7S DNA are coincident with OriH [27–29] has suggested that 7S DNA may represent either an abortive replication product or a replication primer [30]. However, the D-loop is rapidly turned over, with a half-life of approximately 1 h, and around 95% of replication initiation events result in 7S DNA synthesis rather than full-length mtDNA replication [31,32]. A clear precursor–product relationship between 7S DNA and replication of full-length mtDNA has been elusive, and so the exact reason why the D-loop is maintained and turned over, at significant energetic cost, remains unclear [33].

Unlike nuclear gene expression, protein synthesis in mitochondria is not compartmentalized, with transcription and translation both taking place within the mitochondrial matrix. Mitochondrial transcripts are processed within structures termed RNA granules [34], found adjacent to the mtDNA, and their protein products are embedded directly into the IMM by the mitoribosome during translation [35–37]. The ability of mtDNA to diffuse freely around the mitochondrial network is limited [38]. Mitochondrial dynamics, that is, fission and fusion of the mitochondrial network, is required in order to facilitate the distribution of mtDNA within the cell [39–41]. The mitochondrial function of a cell can therefore be affected either by a depletion in the number of mtDNA molecules, or by a loss of mtDNA stability (in the form of deletions or mutations) in a subset of the mtDNA molecules within a cell [5].

3. Topological considerations for mtDNA

Despite being a circular genome of bacterial origin, mtDNA has a number of unusual features that confounds simple comparisons with bacterial mechanisms of DNA topology control. Many of the proteins that replicate and transcribe mtDNA are homologous to bacteriophage proteins, rather than to bacterial proteins. This includes the mitochondrial DNA polymerase catalytic subunit POLGA, the replicative helicase TWINKLE and the RNA polymerase POLRMT, all of which show homology to proteins of the T-odd lineage of bacteriophages [42,43]. The T7 DNA polymerase uses the E. coli host thioredoxin as an accessory factor [44], a role that is functionally replaced by the accessory factor POLGB in mitochondria [45,46]. Other essential proteins of the mtDNA replication machinery, such as mitochondrial single-stranded DNA-binding protein (mtSSB) and topoisomerases, are either of bacterial origin or shared with the nucleus [47–49], as may be predicted from the endosymbiotic theory. Mitochondria operate an unusual asynchronous method of DNA replication [50,51] and do not appear to possess a machinery and mechanism for homologous recombination [52], both of which have implications for mtDNA topology control. Topological domains within mtDNA, if present, would presumably be determined by the orientation...
of transcription units and replication origins, and by potential interactions with the IMM, and will be discussed in the following sections.

3.1. mtDNA packaging

Like nuclear and bacterial chromosomes, mitochondrial DNA is packaged into an ordered nucleoprotein complex that, by analogy to bacterial chromosomes, is termed the nucleoid [53]. In microscopy images, nucleoids can be visualized as punctate foci uniformly spread throughout the mitochondrial network (figure 1b) [4,54,55]. The more recent application of super-resolution microscopy techniques to mtDNA has determined that the majority of nucleoids contain only a single-mtDNA molecule rather than consisting of mtDNA multimers [56,57], suggesting that mitochondrial genomes act as functionally independent units. Nonetheless multimeric mtDNAs, and more complex junction-containing mtDNA forms, have also been described in cells [58], and particularly in human cardiac tissue, using gel-based methods and electron microscopy [59,60]. The mechanisms and proteins involved in the formation of these multimeric structures remain poorly understood, but may result from particularly high levels of stalled or aberrant mtDNA replication intermediates in the heart.

A large number of proteins that interact with nucleoids have been identified using immunoprecipitation and proximity biotinylation [61–64]. However, the primary nucleoid protein involved in the packaging of mtDNA is the bifunctional mtDNA packaging and transcription factor TFAM (figure 1c) [65]. TFAM is abundant enough to entirely coat mtDNA [56,66,67], and ChIP-seq data have indicated that TFAM binds throughout the mitochondrial genome [68]. The binding of TFAM causes sharp U-turns in the DNA both at promoters [69,70] and in a non-sequence specific manner [71,72]. TFAM shows cooperative binding to mtDNA [57,73,74] and cross-strand binding [57] that explains how the mitochondrial genome is compacted from a contour length of around 5 µm, for unbound mtDNA, into a structure with a diameter of 100 nm in vivo (figure 1d) [56].

It appears likely that the degree of packaging of mtDNA by TFAM acts to regulate transcription and replication activity within mitochondria. The binding of DNA by TFAM in the presence of the mitochondrial type IB topoisomerase TOP1MT induces supercoiling in vitro [75], highlighting the topological changes that are created during mtDNA packaging. At physiological TFAM concentrations, nucleoids of different packaging densities can be observed, ranging from small and densely packaged complexes to large and mostly unbound mtDNA [57,76,77]. By
reconstituting nucleoid packaging \textit{in vitro} it has been found that a dense packaging of nucleoids inhibits transcription and replication. Although TFAM is required for these processes as an essential transcription factor, high levels of TFAM binding presumably restrict access to the required \textit{cis}-elements. This has led to the suggestion that small changes in the concentration of TFAM could cause large alterations to mtDNA transcription, and thereby act as a method to modulate mitochondrial gene expression and mtDNA replication [76]. Consistent with this idea, nucleoids have been observed using microscopy that are actively undergoing DNA synthesis but show very little TFAM staining [78], suggesting that unpackaged nucleoids could be linked to gene expression and replication while more compact nucleoids are used for mtDNA storage.

3.2. Membrane association of mtDNA

The attachment of mtDNA to membrane structures, either at the origins of replication or elsewhere, has consequences for the formation of topological domains, cationed DNA replication products and DNA segregation. Clear associations between mtDNA and the mitochondrial membrane have been described in non-human systems that aid in the segregation of mtDNA following replication. For example, in trypanosomes, the tripartite attachment complex (TAC) spans the double mitochondrial membrane to directly link the kinetoplast DNA (kDNA) to the basal body of the flagellum to drive kDNA segregation [79]. Double membrane-spanning structures have also been described in budding yeast that may link mtDNA replication to segregation of the replicated genome by mitochondrial dynamics [80,81]. Similarly, human mtDNA is also found closely associated with the cristae structure of the IMM [53,82], although the identity of factors responsible, and specific loci for attachment within mtDNA, have been more elusive. An early EM study found a protein complex of membrane derivation to be associated with the OriH region of mtDNA [83], although the proteins involved have not been identified. The localization of the mitochondrial replicative helicase TWINKLE to the IMM suggests that, at least during replication, mtDNA is membrane-bound [84], which would inhibit the formation of interlinks between replicating mtDNA molecules. The structure and lipid composition of the IMM are also important determinants of mtDNA distribution and stability. The study of this relationship is made challenging by the fact that mtDNA-encoded proteins are themselves structural components of the cristae membranes. Nevertheless, mtDNA is found at regions of high cholesterol content [85] and defects in the biogenesis of cholesterol affect the stability of mtDNA [86,87], suggesting a role in mtDNA attachment or maintenance. The link between mtDNA and mitochondrial membrane structure has also been covered in detail elsewhere [88,89].

4. Topoisomerases and mitochondria

In a covalently closed circular DNA molecule such as mtDNA, there are no free DNA ends that can rotate in order to relieve topological strain, and the linking number of the DNA molecule is therefore fixed. In such topologically constrained molecules, transactions between proteins and the DNA duplex create overwound and underwound regions of DNA, called positive and negative supercoils (figure 2a). Positive supercoiling represents the tightening of the DNA duplex, and unresolved positive supercoiling will eventually inhibit the progression of DNA and RNA polymerases. Negative supercoiling represents the opening of dsDNA and promotes replication and transcription initiation, as well as the formation of D-loops and other alternative DNA structures [90]. In order to be able to manipulate DNA supercoiling, cells use a family of enzymes called topoisomerases [13]. A topoisomerase creates a transient break in the DNA backbone that can be used to untwist and untangle DNA before the break is resealed. Topoisomerases play essential roles in DNA packaging, transcription, DNA replication and recombination [13].

4.1. Topoisomerase mechanisms

Topoisomerases are divided into sub-groups depending upon whether they break one strand of DNA (type I) or both strands of dsDNA (type II), with these two types further subdivided according to their reaction mechanism. The human genome encodes six topoisomerases, with two each of type IA (TOP3A and TOP3B), type IB (TOP1 and TOP1MT) and type IIA (TOP2A and TOP2B). Type IA and type IIA enzymes both employ an enzyme-bridged strand-passage mechanism to alter DNA topology. These enzymes create a break in the DNA (in ssDNA for type IA or in dsDNA for type IIA), then an intact DNA strand is passed through the break, and the break is resealed (figure 2b,c). If the broken and passed strands originate from the same DNA molecule then the result is relaxation of the DNA, whereas if the strands are from separate molecules then the result is the linking (catenation) or unlinking (decatenation) of the two molecules [91]. Type IB topoisomerases, on the other hand, act by creating a nick in dsDNA and allowing the nicked strand to undergo a controlled rotation around the intact strand in order to relieve topological tension within the DNA molecule (figure 2d) [91]. This mechanism allows type IB topoisomerases to regulate intramolecular supercoiling, while the strand-passage mechanism of type IA and IIA topoisomerases additionally permits a role in the decatenation of interlinked DNA replication intermediates.

4.2. The localization and function of human topoisomerases

A prerequisite for a topoisomerase to act upon mtDNA is that it colocalizes with mtDNA in the mitochondrial matrix. The import of proteins into mitochondria is a highly controlled process, as a result of the requirement that the IMM be impermeable to protons in order to carry out OXPHOS. Mitochondrial proteins are directed for import using specialized targeting sequences that can often, but not always, be predicted computationally [8]. Assigning mitochondrial localization to a protein is made challenging by the lack of targeting sequence consensus, and by the fact that targeting sequences are not always located at the N-terminus of the protein. A determination of mitochondrial localization must therefore be made based upon a combination of computational predictions and empirical observation.
The two human type IA topoisomerases, TOP3A and TOP3B, are homologous to the *E. coli* topoisomerase III. TOP3A has a dual localization within mammalian cells, with isoforms targeted to either the nucleus or the mitochondria depending upon the choice of translation start site [40,92,93]. Translation from an upstream start site generates an isoform of TOP3A that bears an N-terminal mitochondrial targeting sequence, whereas translation from a downstream start site generates a shorter isoform of TOP3A that lacks this targeting sequence and localizes to the nucleus [92].

The nuclear form of TOP3A forms a complex together with the OB-fold proteins RMI1 and RMI2, and the RecQ-family helicase BLM, collectively called the BTRR complex [94–96]. This complex is required for the non-crossover resolution (dissolution) of Holliday junctions that arise during DNA recombination [95,97]. Interestingly, nuclear TOP3A has also recently been shown to have the capacity to cooperate with the DNA translocase PICH to introduce positive supercoils [98]. The removal of DNA interlinks by TOP2A is stimulated by positive supercoiling [99], suggesting that the introduction of positive supercoils into interlinked chromosomal DNA by the coordinated action of TOP3A and PICH may act to promote the subsequent removal of these interlinks by TOP2A at the onset of anaphase [98]. However, these binding partners of nuclear TOP3A do not appear to also localize to mitochondria [93], and it is unclear if they are functionally replaced by other factors. The mitochondrial isoform of TOP3A instead appears to be involved in the decatenation of mtDNA molecules during replication, described further in section 6.

TOP3B is unique in being able to process RNA substrates, and localizes to both the nucleus and the cytosol. TOP3B forms a complex with TDRD3 and appears to play a role in the regulation of nuclear transcription, possibly through preventing the formation of R-loops, with the loss of TOP3B resulting in neurological phenotypes [100–103]. Cytosolic TOP3B is found associated with polyribosomes, suggesting that the RNA topoisomerase activity of TOP3B may additionally be required to resolve topological problems with mRNA during translation [104].

The two human type IB topoisomerases, TOP1 and TOP1MT, are expressed from paralogous genes [105]. These two genes have diverged and become specialized for different cellular compartments, with the TOP1 sequence possessing a number of nuclear localization signals that direct it to the nucleus, while TOP1MT encodes an N-terminal mitochondrial targeting sequence that results in its exclusive localization to mitochondria [105,106]. TOP1 has a well-characterized role in regulating supercoiling during nuclear transcription [107,108]. The loss of TOP1MT expression is associated with the dysregulation of mitochondrial transcript levels, suggesting a comparable role for TOP1MT in mitochondria [109,110]. TOP1MT additionally has a proposed role in the regulation of mitochondrial translation [111,112].

---

**Figure 2.** DNA supercoiling and topoisomerase mechanisms. (a) DNA supercoiling. A relaxed circular DNA molecule adopts a circular conformation (top). The underwinding of this DNA molecule causes the formation of negative supercoils (lower left), while the overwinding of this DNA causes the formation of positive supercoils (lower right). (b) Mechanism of type IA topoisomerases. A transient break is created in ssDNA, an intact strand is passed through the gap and the break is resealed. This strand-passage mechanism permits the removal of negative supercoiling (left) or the decatenation of single-stranded linkages such as hemicatenanes (right) depending upon the structure of the substrate. (c) Mechanism of type IIA topoisomerases. A transient break is created in dsDNA, an intact dsDNA strand is passed through the gap, and the break is resealed. This mechanism allows the removal of supercoiling (left) or the decatenation of interlinked dsDNA molecules (right). (d) Mechanism of type IB topoisomerases. A nick is introduced into dsDNA, and then the DNA is allowed to undergo a controlled rotation in order to dissipate either positive or negative supercoiling.
TOP1MT is not an essential gene in mice, although knockout animals show alterations to mtDNA supercoiling as well as phenotypes associated with impaired mitochondrial function, also consistent with a role for TOP1MT in mtDNA gene expression [113,114].

The two human type II topoisomerases, TOP2A and TOP2B, play separate roles in nuclear DNA maintenance and expression. TOP2A is only expressed in actively dividing cells [115,116], where it is required for the removal of chromosome interlinks during anaphase [117–119]. TOP2B, alternatively, is constitutively expressed [120] and has a primary function in transcription regulation [115,121]. There is evidence of localization of both TOP2 isoforms to mitochondria in human cells. A number of early studies detected the presence of TOP2 activity in mitochondrial extracts [122–125], while more recent studies have observed mitochondrial localization using cell fractionation, confocal microscopy and mass spectrometry [114,126,127]. Mitochondrially localized TOP2 isoforms have been suggested to be involved in mtDNA replication [48,127] and in the maintenance of the mtDNA D-loop [114]. Our own localization data has not found evidence for either TOP2A or TOP2B in mitochondria [93]. Neither TOP2A nor TOP2B possess a recognizable mitochondrial targeting sequence, and so it remains to be determined if and how these two proteins are targeted for mitochondrial import.

Transcription in mitochondria is polycistronic, generating near genome-length transcripts that are cleaved by the endoribonucleases RNaseP [128] and ELAC2 [129,130] to release individual mt-mRNAs, mt-tRNAs and mt-rRNAs [131].

A series of elegant biochemical and structural studies have culminated in a model for the initiation of mtDNA transcription from both LSP and HSP. Initiation requires three proteins: the mitochondrial RNA polymerase, POLRMT; and two transcription factors, TFAM and TFB2M [132]. First, TFAM binds upstream of the transcription start site (TSS), inducing a sharp bend in the DNA [69,70], and recruits POLRMT to the TSS [133,134]. TFB2M then binds and aids melting of the promoter DNA [135], allowing RNA synthesis to initiate (figure 3a). Once the initiation factors have been released, the transcription elongation factor TEFM is recruited to the transcribing polymerase and increases the processivity of POLRMT to allow the synthesis of long polycistronic transcripts (figure 3b) [138–141].

Transcription from LSP is believed to be terminated by the protein mTERF1, which binds strongly to the mt-RNA(LewalUR) locus (figure 3c) [142]. mTERF1 exhibits a polarity in its DNA binding, preferentially terminating transcription from the direction of LSP [143–145].

The mechanism of transcription termination for transcripts initiated from HSP remains less well defined, although termination has been observed to occur in the vicinity of TAS (figure 3c) [146–148]. The presence of L-strand RNA beyond TAS, spanning the mtDNA control region, has also been described in some circumstances [110,146,148–151].

5. mtDNA topology during mitochondrial transcription

5.1. Transcription units and mechanism

Mitochondrial DNA is transcribed from two promoters, LSP and HSP, which are located close together, and on opposite strands, in the mtDNA NCR [17]. Transcription initiation from LSP also generates a primer for the initiation of mtDNA replication, as discussed in the next section.

A moving transcription machinery creates localized regions of positive supercoiling ahead of the RNA polymerase and negative supercoiling behind [152,153]. In a small circular genome such as mtDNA, domains of differential supercoiling can be created either by the anchoring of the DNA to an immobile structure (such as the IMM), or by the presence of..
transcription units oriented in opposite directions [152]. As discussed in section 3, it remains unclear if and how mtDNA can freely rotate in order to relieve topological strain is unknown. Because the two mtDNA promoters are located on opposite strands, and oriented in opposite directions, simultaneous transcription from both LSP and HSP would be expected to create domains of positive and negative supercoiling, in front of and behind the two advancing RNA polymerases. However, the close proximity of HSP and LSP initiation complexes [154] suggests the possibility that transcription from the two promoters is coordinated. LSP and HSP also have differing TFAM requirements for activation in vitro [132,155]. A clearer picture of the relative regulation of LSP and HSP in vivo would allow a better understanding of the topology of mtDNA during transcription.

The mitochondrial type IB topoisomerase, TOP1MT, has been linked to the regulation of mtDNA topology during transcription. TOP1MT physically interacts with POLRMT and has been observed to localize to transcriptionally active nucleoids [109], suggesting that it is involved in removing transcription-associated supercoiling. As a type IB topoisomerase, TOP1MT has the capacity to remove both positive and negative supercoiling and so could act either ahead of, or behind, the mitochondrial transcription machinery. Interestingly, the knockout of TOP1MT is associated with increased negative supercoiling of mtDNA [114], as well as an increased level of mtDNA-encoded transcripts. This suggests that, unless changes to transcript levels are mediated post-transcriptionally, that the action of TOP1MT normally acts to repress transcription [109,110]. TOP1MT knockout mice additionally accumulate non-coding L-strand RNA from the control region, indicative of transcription proceeding past its normal termination site close to TAS [110]. Binding sites for TOP1MT have been mapped to the mtDNA control region, including the promoter region [156,157]. Taken together, these results suggest that the control of mtDNA topology by TOP1MT is normally required to regulate mtDNA transcription initiation and possibly termination.

The potential roles of other mitochondrial topoisomerases in removing transcription-associated supercoiling are yet to be studied, although treatment of cultured cells with compounds known to target TOP2 isoforms has been found to result in a reduction of the steady-state levels of some mitochondrial transcripts [127].

Unresolved supercoiling would eventually be expected to inhibit the progress of the mitochondrial transcription machinery, resulting in premature transcription termination. The tRNA punctuation model dictates that mitochondrial RNAs are synthesized in equimolar ratios as polycistrionic transcripts before being processed [131]. The inhibition of transcription progression would therefore lead to a depletion of promoter-distal transcripts; a phenotype that is also seen upon the loss of the transcription elongation factor TEFM [138,141].

### 6. mtDNA topology during DNA replication

#### 6.1. Mechanism of mtDNA replication

A small number of core proteins are minimally required to synthesize mtDNA. The mitochondrial DNA polymerase, POLγ, is a heterotrimer consisting of one catalytic subunit, POLGA, and two copies of an accessory subunit, POLGB [158]. POLγ alone is unable to synthesize DNA using a dsDNA template, and a helicase is required to unwind the dsDNA ahead of the replication fork [159]. The replicative helicase in mitochondria, TWINKLE, forms a hexamer and unwinds dsDNA in the 5' to 3' direction [43,160]. Additionally, mtSSB stimulates the processivity of POLγ and the helicase activity of TWINKLE [159,161]. A dedicated primase has not been identified for mtDNA replication, and usually the RNA primers for mtDNA replication are created by the mitochondrial RNA polymerase POLRMT [162,163].

Human mtDNA contains two canonical replication origins, oriented in opposite directions, termed OriH and OriL. OriH is located in the NCR, close to LSP, whereas OriL is located in a cluster of tRNAs around 10 kb downstream of OriH. Replication from OriH begins with transcription initiation by POLRMT from LSP, with this transcription terminating in a region of conserved sequence blocks (CSBs) located between LSP and OriH (figure 4a). The 3' end of this primer has been mapped predominantly to CSB II, suggesting that RNA-DNA transitions take place in this region [28,164,165]. CSB II is GC-rich, and the formation of a G-quadruplex structure between the primer RNA and the non-template H-strand produces a stable R-loop [166–168]. The processing of the 3' end of this R-loop by RNASEH1 generates a 3' end that can be used by POLγ to initiate replication in a reconstituted system [169]. An essential role for mtSSB in directing primer formation during mtDNA replication initiation has also recently been described [170].

Replication initiation from OriL is also primed by POLRMT. In this case, POLRMT recognizes a stem-loop structure that forms in the single-stranded OriL sequence to generate an RNA primer from a poly(T) stretch in the loop of the hairpin [162,163]. Because the formation of this stem-loop requires OriL to be in a single-stranded conformation, leading-strand replication from OriH (figure 4b) must reach and displace the OriL sequence before lagging-strand synthesis can be initiated (figure 4c) [171,172]. This leads to a substantial delay between replication of the two mtDNA strands.

The exact mechanism of mtDNA replication has been the subject of a substantial amount of debate [51,173,174]. The strand displacement model, formed on the basis of early electron microscopy studies of replicating mouse mtDNA [171], proposes that the displaced parental H-strand is coated with mtSSB during the period between replication initiation at OriH and initiation at OriL. The stem-loop structure at OriL excludes mtSSB from binding at this site, in order to permit primer synthesis by POLRMT [163].

A separate model, known as ‘ribonucleotide incorporation throughout the lagging strand’ (RITOLS), proposes that the displaced H-strand is instead coated by RNA [175–177]. This RNA was later found to be sourced from processed transcripts that are hybridized to the displaced H-strand as the DNA polymerase complex advances, termed the ‘bootlace’ mechanism [178]. A protein machinery for achieving this, as yet, has not been identified.

Fully double-stranded mtDNA replication intermediates, resulting from the simultaneous synthesis of the leading and lagging strands, can also be observed. This strand-coupled mode of mtDNA replication was put forward mostly using evidence from neutral two-dimensional agarose gel
electrophoresis (2D-AGE) data, which shows the existence of mtDNA replication intermediates that migrate similarly to dsDNA structures that can be visualized using the same method in yeast and bacteria [179,180]. Due to the asymmetric nature of mtDNA replication, the termination events for mtDNA synthesis take place in different locations for each parental strand. The topoisomerase TOP3A is required for the decatenation of replicated mtDNA molecules (figure 4), as large catenated networks of mtDNA accumulate in the absence of mitochondrial TOP3A activity. Replication termination events have been broadly mapped to the OriH region, suggesting that this is a primary site of mtDNA replication termination [93].

The potential for conflict between replication and transcription also presents a risk for mtDNA topology. Replication initiation from OriH proceeds in the opposite orientation to transcription from HSP, creating the possibility of collisions between the replication and transcription machineries. Whether transcription and replication occur simultaneously within the same mtDNA molecule, beyond the necessity of transcription initiation at LSP to prime replication from OriH remains poorly understood. As noted previously, the proximity of LSP and HSP suggests the possibility that initiation from these two sites is regulated [154]. The mitochondrial transcription termination factor mTERF1, which binds to the mt-tRNA^Lys(UUR) locus and preferentially terminates transcription from LSP [143–145] also shows contrahelicase activity that serves to pause mtDNA replication [181,182]. This suggests the possibility that this locus, and the action of mTERF1, could be used to regulate the bypass of replication and transcription complexes.

**Figure 4.** DNA topology during replication. (a–d) Stages of human mtDNA replication. (a) Transcription initiation from LSP creates an R-loop that is stabilized by a hybrid G-quadruplex formed with the non-template H-strand at conserved sequence block II (CSBII). Processing of this R-loop by RNASEH1 creates a primer for the mitochondrial DNA polymerase POLγ. (b) Mitochondrial DNA synthesis requires POLγ, the helicase TWINKLE and mtSSB. The rotation of the replisome to form precatenanes may be inhibited by the binding of TWINKLE to the IMM. (c) The primer for L-strand replication initiation at OriL is formed by POLRMT, which synthesizes a short primer from a stem-loop structure in the OriL sequence that can be extended by POLγ. (d) During mtDNA replication termination, TOP3A is required to separate the replicated mtDNA molecules. In the absence of TOP3A, a hemicatenane forms in the vicinity of OriH, suggesting that this is the primary site of replication termination. (e–g) DNA topology and decatenation during strand-coupled DNA replication. (e) DNA synthesis creates localized regions of positive supercoiling ahead of the replisome, while rotation of the replisome leads to intertwining of the replicated DNA molecules to form precatenanes. (f) The convergence of replication forks and the eventual removal of hemicatenanes between replicated DNA molecules can be catalysed by the cooperative action of a type IA topoisomerase (such as TopoIII) and a RecQ-family helicase. (g) Precatenanes that remain unresolved following the completion of DNA replication form dsDNA catenanes that require a type II topoisomerase activity for their removal.
6.2. Control of mtDNA topology during mtDNA replication

6.2.1. Comparison with bacterial and bacteriophage DNA replication

The topological forces acting upon replicating circular genomes, and the action of topoisomerases during replication, is best understood in model bacteria such as E. coli. During replication elongation, a moving replisome creates a localized region of positive supercoiling ahead of the replication fork, similar to the situation during transcription. However, compared with transcription, DNA replication bears the added complication of having two nascent daughter DNA molecules behind the replisome, creating the possibility that supercoiling can be dispersed behind the replisome to create intertwines between the two daughter molecules (figure 4f) [183]. If left unresolved, these intertwines, termed precatenanes, lead to the formation of catenated daughter genomes during replication termination that necessitates a type II topoisomerase activity for their removal [184–186].

During replication termination, the convergence of two replication forks either generates a hemicatenane that can be resolved by a type IA topoisomerase such as TopoIII (figure 4f), or complete replication of the molecules forms duplex interlinkages that can be removed by a type II topoisomerase (figure 4g).

The paradigm of E. coli DNA replication indicates that both type I and type II topoisomerases can act to remove chromosome interlinkages during replication elongation and termination. E. coli possesses two type II topoisomerases, gyrase and TopoIV, with gyrase acting primarily to regulate supercoiling and TopoIV acting primarily to remove chromosome interlinkages during replication [187,188]. However, TopoIII, a type IA topoisomerase, can also act as a decatenase by acting upon hemicatenanes and single-stranded regions of un-replicated DNA template both in vitro and in vivo [189–191].

The applicability of this bacterial model to human mitochondrial DNA depends upon both the mechanism of mtDNA replication and the localization of human topoisomerases, in the sense that these factors determine the DNA structures that can be produced and the enzymes present that are capable of processing them.

As previously noted, several proteins of the mtDNA replication machinery are related to bacteriophage proteins of the T-odd lineage [42]. The mitochondrial helicase TWINKLE is related to the T7 gp4 primase-helicase [43], which creates primers for coupled leading- and lagging-strand replication during replication of the phage T7 genome [192]. Replication in T7 results in the formation of linear concatemers that require endonucleolytic processing prior to packaging [193]. By contrast, mitochondrial TWINKLE has lost the primase activity of gp4, with primers instead being synthesized by POLRMT [162,163]. This uncoupling of replication of the two DNA strands may increase the availability of ssDNA regions to act as substrates for type IA topoisomerases.

Pulse labelling studies of replicating mtDNA have suggested that the synthesis of the D-loop removes negative supercoils to produce mtDNA in an open circular form [16,31]. The mitochondrial type IB topoisomerase TOP1MT binds to the mtDNA NCR close to sequence elements that are essential for mtDNA replication, including OriH and TAS at both ends of the D-loop [156,157]. This suggests that TOP1MT could regulate the supercoiling of mtDNA during replication initiation. However, the observation that mtDNA copy number is maintained in the absence of TOP1MT activity [93,114] suggests that this activity would not be essential, or alternatively that it can be performed by another mitochondrial topoisomerase in the absence of TOP1MT. When both TOP1MT and TOP3A are depleted from human cells, severe defects in mtDNA maintenance are observed [93] that may support the idea that TOP3A can compensate for the absence of TOP1MT in the removal of negative supercoiling during mtDNA replication.

During the elongation phase of mtDNA replication, the accumulation of positive supercoiling ahead of the replisome may be expected to promote the rotation of the replisome, resulting in the formation of precatenanes. These precatenanes could be removed by TOP3A, using ssDNA regions in the replicating DNA for strand passage. Precatenanes that are left unresolved following the completion of DNA synthesis would require a type II topoisomerase activity (TOP2A or TOP2B) for their removal. However, an association between the mitochondrial replisome and the mitochondrial inner membrane during mtDNA replication [84] may prevent this rotation of the replisome and therefore inhibit the formation of intertwines between the two daughter mtDNA molecules. In this case, topoisomerase activities would be required to remove localized regions of supercoiling ahead of, and behind, the replisome. Negative supercoiling could be resolved by TOP1MT, TOP3A or a type II topoisomerase, whereas positive supercoiling could only be resolved by TOP1MT or a type II topoisomerase.

6.2.2. mtDNA replication initiation and elongation

In strand displacement mtDNA replication, the initiation of mtDNA synthesis from OriH can produce either 7S DNA (to form the D-loop) or initiate full-length mtDNA replication. Pulse labelling studies of replicating mtDNA have suggested that the synthesis of the D-loop removes negative supercoils to produce mtDNA in an open circular form [16,31]. The mitochondrial type IB topoisomerase TOP1MT binds to the mtDNA NCR close to sequence elements that are essential for mtDNA replication, including OriH and TAS at both ends of the D-loop [156,157]. This suggests that TOP1MT could regulate the supercoiling of mtDNA during replication initiation. However, the observation that mtDNA copy number is maintained in the absence of TOP1MT activity [93,114] suggests that this activity would not be essential, or alternatively that it can be performed by another mitochondrial topoisomerase in the absence of TOP1MT. When both TOP1MT and TOP3A are depleted from human cells, severe defects in mtDNA maintenance are observed [93] that may support the idea that TOP3A can compensate for the absence of TOP1MT in the removal of negative supercoiling during mtDNA replication.

During the elongation phase of mtDNA replication, the accumulation of positive supercoiling ahead of the replisome may be expected to promote the rotation of the replisome, resulting in the formation of precatenanes. These precatenanes could be removed by TOP3A, using ssDNA regions in the replicating DNA for strand passage. Precatenanes that are left unresolved following the completion of DNA synthesis would require a type II topoisomerase activity (TOP2A or TOP2B) for their removal. However, an association between the mitochondrial replisome and the mitochondrial inner membrane during mtDNA replication [84] may prevent this rotation of the replisome and therefore inhibit the formation of intertwines between the two daughter mtDNA molecules. In this case, topoisomerase activities would be required to remove localized regions of supercoiling ahead of, and behind, the replisome. Negative supercoiling could be resolved by TOP1MT, TOP3A or a type II topoisomerase, whereas positive supercoiling could only be resolved by TOP1MT or a type II topoisomerase.

6.2.3. mtDNA decatenation

The loss of mitochondrial TOP3A activity is associated with the accumulation of catenated mtDNA replication termination intermediates, centred around the OriH region, indicating a role for TOP3A in mtDNA decatenation [93]. The junctions between these molecules resemble hemicatenanes, consistent with the known catalytic activity of TOP3A [93]. However, an outstanding question is whether this hemicatenated termination structure around OriH represents a physiological intermediate that forms in vivo, or whether TOP3A normally acts to unlink mtDNA replication intermediates during replication elongation. As a type IA topoisomerase, TOP3A would require regions of ssDNA in the template DNA in order to remove intertwines between mtDNA replication intermediates. This could be facilitated by long regions of ssDNA present in the lagging strand template, according to the strand displacement model of mtDNA replication, or by short ssDNA regions in strand-coupled replication intermediates. Terminal mtDNA replication intermediates have also been observed around the OriH region using 2D-AGE in wild-type cells containing TOP3A activity [179,194,195], supporting the idea that OriH can act as a replication terminus under normal conditions.
Whether other enzymes also contribute to mtDNA decatenation remains unclear. The nuclear binding partners of TOP3A, the helicase BLM, and the OB-fold proteins RM1 and RM2 [94–96,196], have not been observed to localize to mitochondria [93]. The binding of RM1 to nuclear TOP3A stimulates the decatenation activity of TOP3A both in yeast [197] and in humans [196,198], although it is not absolutely required for this activity. During the binding of RM1 to TOP3A, a loop from RM1, termed the decatenation loop, is inserted close to the active site of TOP3A [199]. The decatenation loop is believed to stabilize the gate of TOP3A in a more open conformation and promote its decatenation activity [199,200]. The apparent absence of RM1 from mitochondria, in which the decatenation activity of TOP3A is essential for mtDNA segregation, therefore seems curious. An interesting observation is that the binding of RM1 to nuclear TOP3A constrains the size of the gate through which the transferred DNA strand is passed during decatenation [97,199]. It is possible that, in the absence of RM1, this gate would be large enough to accommodate dsDNA during strand passage, as is the case with E. coli Topoll [201]. If this were the case then mitochondrial TOP3A could act upon a broader range of substrates than currently assumed. For example, TOP3A could potentially decatenate replication intermediates throughout much of the mitochondrial genome during replication elongation, or use the D-loop as a substrate to regulate mtDNA supercoiling.

The cooperation between TOP3 and a RecQ-family helicase (such as BLM) is conserved in both yeast [202] and E. coli [203], suggesting a conserved function of the complex. A mitochondrial localization has been reported for the RecQ-family helicase RECQL4 [204–206], and this or another mitochondrial DNA helicase could functionally replace BLM during mtDNA maintenance. Alternatively, it is possible that the lack of homologous recombination within mitochondria to create double Holliday junctions [52], together with an asynchronous mode of DNA replication that avoids the creation of converging dsDNA replication forks, obviates the requirement for a helicase to work together with TOP3A in mitochondria.

A type II topoisomerase could play a role in mtDNA replication either by regulating supercoiling during replication elongation or by decatenating replicated mtDNA, comparable to their roles in the nucleus or in bacteria. Depletion of TOP2 has been found to result in a reduction of mtDNA copy number in one study [127] but not in another [93]. The loss of either TOP2A or TOP2B does not appear to affect the catenation state of mtDNA, arguing against a role of a TOP2 isoform in mtDNA decatenation, but does appear to affect mtDNA supercoiling [93,127]. Drugs that target TOP2 have been observed to affect mtDNA replication rates [127], although it remains to be determined whether this toxicity represents a direct effect within mitochondria mediated via TOP2.

7. Topoisomerases in human mitochondrial disease

Missense variants in TOP3A were initially reported in a single individual with an adult-onset mitochondrial disease characterized by progressive external ophthalmoplegia and cerebellar ataxia. On a molecular level, these variants were associated with mtDNA instability (in the form of multiple mtDNA deletions) and the presence of high molecular weight catenated forms of mtDNA [93]. These clinical and molecular features are similar to those associated with some pathological variants in other factors involved in mtDNA replication, such as POLY and TWINKLE [207]. Subsequently, a cohort of ten patients was described with a disorder of growth restriction and microcephaly, associated with truncating variants in TOP3A [208]. This disorder shares a number of features with Bloom syndrome, which is caused by biallelic loss-of-function mutations in BLM, one of the binding partners of TOP3A in the nucleus. However, a number of these patients with truncating variants in TOP3A also exhibited cardiomyopathy, not typically observed in Bloom syndrome, that is likely to be attributable to the loss of activity of the mitochondrial isoform of TOP3A [208]. A further two siblings were also recently reported with a Bloom syndrome-like disorder with cardiomyopathy and mitochondrial dysfunction, resulting from compound heterozygous truncating and missense variants in TOP3A [209]. The relative contributions of the nuclear and mitochondrial isoforms of TOP3A to the clinical features of TOP3A-related disease warrant further investigation.

Variants in TOP1MT are not currently directly implicated in monogenic mitochondrial disease. However, two major single nucleotide variants in TOP1MT have been found to affect the catalytic activity of the protein [210] and could potentially act as modifiers for other variants found in mitochondrial DNA disease.

Compounds that target type II topoisomerases have also been implicated in mitochondrial dysfunction. The chemotherapeutic agent doxorubicin targets both TOP2 isoforms [211], and cardiomyopathy caused by doxorubicin treatment is associated with mitochondrial damage [212]. Other antibiotics such as fluoroquinolones, which are associated with tendinitis in a small number of cases [213], target bacterial type II topoisomerases. Both families of compounds have been suggested to inhibit TOP2 within mitochondria [127], and clarifying the mechanism of action of these drugs and their effects upon mtDNA maintenance is of therapeutic importance.

8. Concluding remarks

Maintaining the topological homeostasis of DNA during transcription, replication and packaging is essential for genome stability. In mitochondria, defects in the maintenance of the multicopy mitochondrial genome impact upon the bioenergetic role of mitochondria within the cell and can lead to human mitochondrial disease. Topoisomerases are required both for maintaining mtDNA supercoiling and for mtDNA decatenation and segregation. Molecular roles for two mitochondrial type I topoisomerases, TOP3A and TOP1MT, have been described but further investigation is required to determine the roles of mtDNA topology and packaging in the regulation of mitochondrial gene expression and mtDNA replication. Our future understanding of how mtDNA topology is controlled will be informed by a better understanding of how topological domains in mtDNA are formed during mtDNA expression and replication, and by association with the mitochondrial membrane. In recent years, pathological variants in TOP3A, which has both mitochondrial and nuclear isoforms, have been found to underlie cases of human disease. Understanding the relative contributions of these two isoforms to these disease phenotypes necessitates further study, as does
the mechanism of action of drugs that inhibit or poison topoisomerases and result in mitochondrial toxicity.

Data accessibility. This article does not contain any additional data.

Authors’ contributions. All authors contributed to the writing and editing of the manuscript.

Competing interests. We declare we have no competing interests.

References

1. Gray MW, Burger G, Lang BF. 1999 Mitochondrial evolution. Science 283, 1476–1481. (doi:10.1126/science.2835407.1476)
2. Gabaldon T, Huynen MA. 2003 Reconstruction of the proto-mitochondrial metabolism. Science 301, 609. (doi:10.1126/science.1085463)
3. Calvo SE, Moother VK. 2010 The mitochondrial proteome and human disease. Annu. Rev. Genomics Hum. Genet. 11, 25–44. (doi:10.1146/annurev-genom-082509-141720)
4. Satoch M, Kuroiwa T. 1991 Organization of multiple nucleoids and DNA molecules in mitochondria of a human cell. Exp. Cell Res. 196, 137–140. (doi:10.1016/0014-8482(91)90467-9)
5. Gorman GS et al. 2016 Mitochondrial diseases. Nat. Rev. Dis. Primers 2, 16080. (doi:10.1038/nrdp.2016.80)
6. Rath S. 2017 Mitochondrial genome as a target in mouse models of mitochondrial diseases. Exp. Cell Res. 360, 246–258. (doi:10.1016/j.yexcr.2014.03.027)
7. Smith AC, Robinson AJ. 2019 Mitominer v4: an updated database of mitochondrial localization evidence, phenotypes and diseases. Nucleic Acids Res. 47, D1225–D1228. (doi:10.1093/nar/gky1072)
8. Wiedemann N, Pfanner N. 2017 Mitochondrial machineries for protein import and assembly. Annu. Rev. Biochem. 86, 685–714. (doi:10.1146/annurev-biochem-060815-014402)
9. Pearce SF, Rebello-Guipar M, D’Souza AR, Powell CA, Van Haute L, Minczuk M. 2017 Regulation of mammalian mitochondrial gene expression: recent advances. Trends Biochem. Sci. 42, 625–639. (doi:10.1016/j.tibs.2017.02.003)
10. Fange G, Falkenberg M. 2019 Organization of DNA in mammalian mitochondria. Int. J. Mol. Sci. 20, 2770. (doi:10.3390/ijms20112770)
11. Dunaway M, Ostender EA. 1993 Local domains of supercoiling activate a eukaryotic promoter in vivo. Nature 361, 746–748. (doi:10.1038/361746a0)
12. Bermejo R, Lai MS, Foiani M. 2012 Preventing replication stress to maintain genome stability: resolving conflicts between replication and transcription. Mol. Cell 45, 710–718. (doi:10.1016/j.molcel.2012.03.001)
13. Vos SM, Trettier EM, Schmidt BH, Berger JM. 2011 All tangled up: how cells direct, manage and exploit topoisomerase function. Nat. Rev. Mol. Cell Biol. 12, 827–841. (doi:10.1038/nrm3228)
14. Anderson S et al. 1981 Sequence and organization of the human mitochondrial genome. Nature 290, 457–465. (doi:10.1038/290457a0)
15. Andrews RM, Kubbaka I, Chinnery PF, Lightowler RN, Turnbull DM, Howell N. 1999 Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat. Genet. 23, 147. (doi:10.1038/13779)
16. Berk AJ, Clayton DA. 1974 Mechanism of mitochondrial DNA replication in mouse L-cells: asynchronous replication of strands, segregation of circular daughter molecules, aspects of topology and turnover of an initiation sequence. J. Mol. Biol. 86, 801–824. (doi:10.1016/0022-2836(74)90355-6)
17. Gustafsson CM, Falkenberg M, Larsson NG. 2016 Maintenance and expression of mammalian mitochondrial DNA. Annu. Rev. Biochem. 85, 133–160. (doi:10.1146/annurev-biochem-060815-014402)
18. Kasamatsu H, Robberson DL, Vinograd J. 1971 A novel closed-circular mitochondrial DNA with properties of a replicating intermediate. Proc. Natl Acad. Sci. USA 68, 2252–2257. (doi:10.1073/pnas.68.9.2252)
19. Amberg A, van Bruggen EF, Borst P. 1971 Presence of DNA molecules with a displacement loop in standard mitochondrial DNA preparations. Biochim. Biophys. Acta 246, 353–357. (doi:10.1016/0005-2787(71)90147-x)
20. Hallberg RL. 1974 Mitochondrial DNA in Xenopus laevis oocytes. I. Displacement loop occurrence. J. Mol. Biol. 86, 252–260. (doi:10.1016/0022-2836(74)90150-3)
21. Robberson DL, Clayton DA. 1972 Replication of mitochondrial DNA in mouse I cells and their thymidine kinase derivatives: displacement replication in standard mitochondrial DNA preparations. Proc. Natl Acad. Sci. USA 69, 3810–3814. (doi:10.1073/pnas.69.12.3810)
22. Annex BH, Williams RS. 1990 Mitochondrial DNA structure and expression in specialized subtypes of mammalian striated muscle. Mol. Cell. Biol. 10, 5671–5678. (doi:10.1128/mcb.10.11.5671)
23. Callen JC, Tourte M, Dennebouy N, Mounolou JC. 1983 Changes in D-loop frequency and superhelicity among the mitochondrial DNA molecules in relation to organelle biogenesis in oocytes of Xenopus laevis. Exp. Cell Res. 143, 115–125. (doi:10.1016/0014-4827(83)90114-3)
24. Brown WM, Shine J, Goodman HM. 1978 Human mitochondrial DNA: analysis of 7S DNA from the origin of replication. Proc. Natl Acad. Sci. USA 75, 735–739. (doi:10.1073/pnas.75.2.735)
25. Kambham C et al. 2013 Loss-of-function mutations in MNGEI impair mtDNA replication and cause multisystemic mitochondrial disease. Nat. Genet. 45, 214–219. (doi:10.1038/ng.2501)
26. Doda JN, Wright CT, Clayton DA. 1981 Elongation of displacement-loop strands in human and mouse mitochondrial DNA is arrested near specific template sequences. Proc. Natl Acad. Sci. USA 78, 6116–6120. (doi:10.1073/pnas.78.10.6116)
27. Crews S, Gjaja D, Posakony J, Nishiguchi J, Attardi G. 1979 Nucleotide sequence of a region of human mitochondrial DNA containing the precisely identified origin of replication. Nature 277, 192–198. (doi:10.1038/277192a0)
28. Kang D, Miyako K, Kai Y, Lee T, Takeshige K. 1997 In vivo determination of replication origins of human mitochondrial DNA by ligation-mediated polymerase chain reaction. J. Biol. Chem. 272, 15 275–15 279. (doi:10.1074/jbc.272.24.15275)
29. Fish J, Raule N, Attardi G. 2004 Discovery of a major D-loop replication origin reveals two modes of human mtDNA synthesis. Science 306, 2098–2101. (doi:10.1126/science.1102077)
30. Clayton DA. 1982 Replication of animal mitochondrial DNA. Cell 28, 693–705. (doi:10.1016/0006-8477(82)90049-6)
31. Bogenhagen D, Clayton DA. 1978 Mechanism of mitochondrial DNA replication in mouse L-cells: kinetics of synthesis and turnover of the initiation sequence. J. Mol. Biol. 119, 49–68. (doi:10.1016/0022-2836(78)90269-3)
32. Gensler S, Weber K, Schmitt WE, Perez-Martos A, Enriquez JA, Montoya J, Wiener RJ. 2001 Mechanism of mammalian mitochondrial DNA replication: import of mitochondrial transcription factor A into isolated mitochondria stimulates 7S DNA synthesis. Nucleic Acids Res. 29, 3657–3663. (doi:10.1093/nar/29.17.3657)
33. Nicholas TJ, Minczuk M. 2014 In D-loop: 40 years of mitochondrial 7S DNA. Exp. Gerontol. 56, 175–181. (doi:10.1016/j.exger.2014.03.027)
34. Jourdain AA, Boehm E, Maundrell K, Martinou JC. 2016 Mitochondrial RNA granules: compartmentalizing mitochondrial gene expression. J. Cell Biol. 212, 611–614. (doi:10.1083/jcb.201507125)
35. Richter-Dennerlein R et al. 2016 Mitochondrial protein synthesis adapts to influx of nuclear-encoded protein. Cell 167, 471–483e410. (doi:10.1016/j.cell.2016.09.003)
36. Zorkau M, Albus CA, Berlinger-Palmieri R, Chrzanowska-Lightowlers ZMA, Lightowlers RN.
47. Forterre P, Gadelle D. 2009 Phylogenomics of DNA
41. Qin J et al.
44. Tabor S, Huber HE, Richardson CC. 1987 Escherichia
38. Gilkerson RW, Schon EA, Hernandez E, Davidson
37. Itoh Y, Andrell J, Choi A, Richter U, Maiti P, Best RB,
48. Goffart S, Hangas A, Pohjoismaki JLO. 2019 Twist
topoisomerases: their origin and putative roles in
38 197
1979.
N-ethylmaleimide resistance.
32. Cold Spring Harbor Perspect. Biol. 4, a012971. (doi:10.1101/cshperspect.a012971)
28. Cold Spring Harbor Perspect. Biol. 4, 287–296. (doi:10.1042/
27. Cold Spring Harbor Perspect. Biol. 4, 251–528. (doi:10.1002/2836(69)90240-x)
26. Cold Spring Harbor Perspect. Biol. 4, 1583–1596. (doi:10.1091/mcb. e02-07-0399)
25. Cold Spring Harbor Perspect. Biol. 4, 134–137. (doi:10.1101/pnas.1109263108)
24. Cold Spring Harbor Perspect. Biol. 4, 3586–3593. (doi:10.1073/pnas.1111111105)
23. Cold Spring Harbor Perspect. Biol. 4, 3567–3578. (doi:10.1101/pnas.1111263105)
22. Cold Spring Harbor Perspect. Biol. 4, 3547–3558. (doi:10.1101/pnas.1111363105)
21. Cold Spring Harbor Perspect. Biol. 4, 3536–3545. (doi:10.1101/pnas.1111253105)
20. Cold Spring Harbor Perspect. Biol. 4, 3518–3528. (doi:10.1101/pnas.1111123105)
21 457. (doi:10.1074/jbc.M109.016600)
20. Cold Spring Harbor Perspect. Biol. 4, 2146–2147. (doi:10.1074/jbc.M109.016600)
19. Cold Spring Harbor Perspect. Biol. 4, 2141–2146. (doi:10.1074/jbc.M109.016590)
18. Cold Spring Harbor Perspect. Biol. 4, 2137–2141. (doi:10.1074/jbc.M109.016525)
17. Cold Spring Harbor Perspect. Biol. 4, 2135–2140. (doi:10.1074/jbc.M109.016497)
16. Cold Spring Harbor Perspect. Biol. 4, 2132–2135. (doi:10.1074/jbc.M109.016400)
15. Cold Spring Harbor Perspect. Biol. 4, 2129–2134. (doi:10.1074/jbc.M109.016373)
14. Cold Spring Harbor Perspect. Biol. 4, 2125–2128. (doi:10.1074/jbc.M109.016324)
13. Cold Spring Harbor Perspect. Biol. 4, 2121–2124. (doi:10.1074/jbc.M109.016282)
12. Cold Spring Harbor Perspect. Biol. 4, 2117–2120. (doi:10.1074/jbc.M109.016230)
11. Cold Spring Harbor Perspect. Biol. 4, 2113–2116. (doi:10.1074/jbc.M109.016180)
10. Cold Spring Harbor Perspect. Biol. 4, 2110–2112. (doi:10.1074/jbc.M109.016098)
9. Cold Spring Harbor Perspect. Biol. 4, 2107–2110. (doi:10.1074/jbc.e090078200)
8. Cold Spring Harbor Perspect. Biol. 4, 2103–2107. (doi:10.1074/jbc.e090047200)
7. Cold Spring Harbor Perspect. Biol. 4, 2099–2103. (doi:10.1074/jbc.e090031200)
6. Cold Spring Harbor Perspect. Biol. 4, 2095–2099. (doi:10.1074/jbc.e090020200)
5. Cold Spring Harbor Perspect. Biol. 4, 2089–2094. (doi:10.1074/jbc.e090010200)
4. Cold Spring Harbor Perspect. Biol. 4, 2083–2087. (doi:10.1074/jbc.e090000200)
3. Cold Spring Harbor Perspect. Biol. 4, 2079–2083. (doi:10.1074/jbc.e090000100)
2. Cold Spring Harbor Perspect. Biol. 4, 2075–2078. (doi:10.1074/jbc.e090000000)
1. Cold Spring Harbor Perspect. Biol. 4, 2071–2074. (doi:10.1074/jbc.e090000000)
components of the mitochondrial transcription machinery. *Proc. Natl Acad. Sci. USA* **109**, 1610–1615. (doi:10.1073/pnas.1119738109)

76. Farge G, Menheimovic M, Blacayon M, van den Wildenberg SM, Roos WH, Gustafsson CM, Wuite GJ, Falkenberg M. 2014 In vitro-reconstituted nucleoids can block mitochondrial DNA replication and transcription. *Cell Rep.* **8**, 66–74. (doi:10.1016/j.celrep.2014.05.046)

77. Brown TA, Tkachuk AN, Shengel G, Kopek BG, et al. Wai T, Teoli D, Shoubridge EA. 2008 The limits, and membrane interaction. *Mol. Cell Biol.* **31**, 4994–5010. (doi:10.1128/MCB.05694-11)

78. Meeusen S, Nunnari J. 2003 Evidence for a two membrane-spanning autonomous mitochondrial nucleoid reveals their spatial range, limits, and membrane interaction. *Mol. Cell Biol.* **17**, 701–721. (doi:10.1038/nrm.2016.111)

79. Stewart L, Redinbo MR, Oju YX, Hol WGJ, Champoux JJ. 1998 A model for the mechanism of human topoisomerase I. *Science* **279**, 1534–1541. (doi:10.1126/science.279.5356.1534)

80. Wang Y, Lyu YL, Wang JC. 2002 Dual localization of human topoisomerase IIalpha to mitochondria and nucleus. *Proc. Natl Acad. Sci. USA* **99**, 12174–12179. (doi:10.1073/pnas.192449499)

81. Nicholls TJ et al. 2018 Topoisomerase IIalpha is required for DNA replication and degradation of human mtDNA. *Mol. Cell* **69**, 9–23e26. (doi:10.1016/j.molcel.2017.11.033)

82. Xu D et al. 2008 RMI, a new OB-fold complex essential for Bloom syndrome protein to maintain genome stability. *Genes Dev.* **22**, 2843–2855. (doi:10.1101/gad.170608)

83. Wu L, Hickson ID. 2003 The Bloom’s syndrome helicase suppresses crossing over during homologous recombination. *Nature* **426**, 870–874. (doi:10.1038/nature02253)

84. Singh TR, Ali AM, Bursigna V, Raymond S, Fan Q, Du CH, Andreassen PR, Sung P, Meetei AR. 2008 BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolution. *Genes Dev.* **22**, 2856–2868. (doi:10.1101/gad.172508)

85. Zhang H, Barcelo JM, Lee B, Kohlhagen G, Zimonjic DB, Poppescu NC, Pommier Y. 2001 Human mitochondrial topoisomerase I. *Proc. Natl Acad. Sci. USA* **98**, 10668–10613. (doi:10.1073/pnas.191321998)

86. Merino A, Madden KR, Lane WS, Champoux JJ, Reinberg D. 1993 DNA topoisomerase I is involved in both repression and activation of transcription. *Nature* **365**, 227–232. (doi:10.1038/365227a0)

87. Baranello L et al. 2016 RNA polymerase II regulates topoisomerase I activity to favor efficient transcription. *Cell* **165**, 357–371. (doi:10.1016/j.cell.2016.02.036)

88. Sebek S et al. 2013 Negative regulation of mitochondrial transcription by mitochondrial topoisomerase I. *Nucleic Acids Res.* **41**, 9848–9857. (doi:10.1093/nar/gkt768)

89. Dalla Rosa I, Zhang H, Khiati S, Wu X, Pommier Y. 2017 Transcription profiling suggests that mitochondrial topoisomerase IIB acts as a topological barrier and regulator of mitochondrial DNA transcription. *J. Biol. Chem.* **292**, 20162–20172. (doi:10.1074/jbc.REV117.135241)

90. Baechler SA et al. 2019 The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis. *Nat. Commun.* **10**, 83. (doi:10.1038/s41467-018-07922-3)

91. Baechler SA, Dalla Rosa I, Spinazzola A, Pommier Y. 2019 Beyond the unwinding: role of TOP1MT in mitochondrial translation. *Cell Cycle* **18**, 2377–2384. (doi:10.1080/15384101.2019.1646563)

92. Douare C, Sourbier C, Dalla Rosa I, Brata Das B, Redon CE, Zhang H, Neckers L, Pommier Y. 2012 Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism. *PLoS ONE* **7**, e41094. (doi:10.1371/journal.pone.0041094)

93. Zhang H, Zhang YW, Yaruskawa T, Dalla Rosa I, Khiati S, Pommier Y. 2014 Increased negative supercoiling of mtDNA in TOP1MT knockout mice and presence of topoisomerases IIBalpha and IIBbeta in vertebrate mitochondria. *Nucleic Acids Res.* **42**, 7259–7267. (doi:10.1093/nar/gku1384)

94. Tiwari VK et al. 2012 Target genes of Topoisomerase IIBeta regulate neuronal survival and are defined by
promoters. *J. Biol. Chem.* **291**, 13 432–13 435. (doi:10.1074/jbc.C116.727966)

155. Uchida A *et al.* 2017 Unexpected sequences and structures of mtDNA required for efficient transcription from the first heavy-strand promoter. *Elife* **6**, e27283. (doi:10.7554/elife.27283)

156. Zhang H, Pommier Y. 2008 Mitochondrial topoisomerase I sites in the regulatory D-loop region of mitochondrial DNA. *Biochemistry* **47**, 11 196–11 203. (doi:10.1021/bi800774b)

157. Dalla Rosa I, Huang SY, Agama K, Khati S, Zhang H, Pommier Y. 2014 Mapping topoisomerase sites in mitochondrial DNA with a poisonous mitochondrial topoisomerase I (Top1mt). *J. Biol. Chem.* **289**, 18 595–18 602. (doi:10.1074/jbc.M114.555367)

158. Yakubovskaya E, Chen Z, Carrodeguas JA, Kisker C, Uchida A, Zeviani M, Falkenberg M, Gustafsson CM. 2010 G-quadruplex structures in mitochondrial DNA replicates bidirectionally from an initiation zone. *J. Biol. Chem.* **278**, 50 961–50 969. (doi:10.1074/jbc.M308022200)

159. Shi Y, Posse V, Zhu X, Hyvarinen AK, Jacobs HT, Falkenberg M, Gustafsson CM. 2016 Mitochondrial transcription termination factor 1 directs polar replication fork pausing. *Nucleic Acids Res.* **44**, 5732–5742. (doi:10.1093/nar/gkv302)

160. Hyvarinen AK, Pohjoismaki JL, Reyes A, Wanrooij S, Yasukawa T, Karhunen PJ, Spellbrink JN, Holt U, Jacobs HT. 2007 The mitochondrial transcription termination factor mTERF modulates replication pausing in human mitochondrial DNA. *Nucleic Acids Res.* **35**, 6458–6474. (doi:10.1093/nar/gkm676)

161. Peter BJ, Ullperger C, Hiasa H, Marians KJ, Cozzarelli NR. 1998 The structure of supercoiled intermediates in DNA replication. *Cell* **94**, 819–827. (doi:10.1016/s0022-2836(02)01075-9)

162. Holm C, Goto T, Wang JC, Botstein D. 1985 DNA topoisomerase II is required at the time of mitosis in yeast. *Cell* **41**, 553–563. (doi:10.1016/0092-8674(85)90028-3)

163. Adams DE, Shekhtman EM, Zechiedrich EL, Schmid MB, Cozzarelli NR. 1992 The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. *Cell* **71**, 277–288. (doi:10.1016/0092-8674(92)90356-h)

164. Baxter J, Diffley JF. 2008 Topoisomerase II inactivation prevents the completion of DNA replication in budding yeast. *Mol. Cell* **30**, 790–802. (doi:10.1016/j.molcel.2008.04.019)

165. Peng H, Marians KJ. 1993 Decatenation activity of topoisomerase I and its role in structure of catenated DNA replication in vitro. *Proc. Natl Acad. Sci. USA* **90**, 8571–8575. (doi:10.1073/pnas.90.18.8571)

166. Zechiedrich EL, Cozzarelli NR. 1995 Roles of topoisomerase IV during orc and pBR322 DNA replication in vitro. *Proc. Natl Acad. Sci. USA* **92**, 8571–8575. (doi:10.1073/pnas.92.18.8571)

167. Hiasa H, DiGaite RJ, Marians KJ. 1994 Decatenation activity of Escherichia coli DNA gyrase and topoisomerase I and III during replication and pBR322 DNA replication in vitro. *J. Biol. Chem.* **269**, 2093–2099. (doi:10.1016/s0021-9258(17)41240-5)

168. Nurse P, Levine C, Hassing H, Marians KJ. 2003 Topoisomerase III can serve as the cellular decatenase in Escherichia coli. *J. Biol. Chem.* **278**, 8653–8660. (doi:10.1074/jbc.M211211200)

169. Lee CM, Wang G, Pertsindis A, Marians KJ. 2019 Topoisomerase III acts at the replication fork to remove catenanes. *J. Bacteriol.* **201**, e00563-18. (doi:10.1128/JB.00563-18)

170. Weigel C, Seitz H. 2006 Bacteriophage replication modules. *EMS Microbiol. Rev.* **30**, 321–381. (doi:10.1111/j.1574-6976.2006.00015.x)

171. White GH, Richardson CC. 1987 Process of concreters of bacteriophage T7 DNA in vitro. *J. Biol. Chem.* **262**, 8851–8860.

172. Pohjoismaki JL, Wanrooij S, Hyvarinen AK, Goffart S, Holt U, Spellbrink JN, Jacobs HT. 2006 Alterations to the expression level of mitochondrial transcription factor A, TFAM, modify the mode of mitochondrial
DNA replication in cultured human cells. Nucleic Acids Res. 34, 5815–5828. (doi:10.1093/nar/gkl703)

195. Hyvarinen AK, Pohjoismaki JL, Holt U, Jacobs HT. 2011 Overexpression of MTERFD1 or MTERFD3 impairs the completion of mitochondrial DNA replication. Mol. Biol. Rep. 38, 1321–1328. (doi:10.1007/s11033-010-0233-9)

196. Yang J, Bachrati CZ, Ou J, Hickson ID, Brown GW. 2010 Human topoisomerase IIIalpha is a single-stranded DNA decatenase that is stimulated by BLM and RMI1. J. Biol. Chem. 285, 21 426–21 436. (doi:10.1074/jbc.M110.123216)

197. Cejka P, Plank JL, Bachrati CZ, Hickson ID, Kowalczykowski SC. 2010 Rmi1 stimulates decatenation of double Holliday junctions during dissolution by Sgs1-Top3. Nat. Struct. Mol. Biol. 17, 1377–1382. (doi:10.1038/nsmb.1919)

198. Wu L et al. 2006 BLAP75/RMI1 promotes the BLM-dependent dissolution of homologous recombination intermediates. Proc. Natl Acad. Sci. USA 103, 4068–4073. (doi:10.1073/pnas.0508295103)

199. Bocquet N et al. 2014 Structural and mechanistic insight into Holliday-junction dissolution by topoisomerase IIalpha and RMI1. Nat. Struct. Mol. Biol. 21, 261–268. (doi:10.1038/nsmb.2775)

200. Cejka P, Plank JL, Dombrowski CC, Kowalczykowski SC. 2012 Decatenation of DNA by the S. cerevisiae Sgs1-Top3-Rmi1 and RPA complex: a mechanism for disentangling chromosomes. Mol. Cell 47, 886–896. (doi:10.1016/j.molcel.2012.06.032)

201. Li Z, Mondragon A, DiGate JR. 2001 The mechanism of type IA topoisomerase-mediated DNA topological transformations. Mol. Cell 7, 301–307. (doi:10.1016/s1097-2765(01)00178-2)

202. Gangloff S, McDonald JP, Bendixen C, Arthur L, Rothstein R. 1994 The yeast type I topoisomerase Top3 interacts with Sgs1, a DNA helicase homolog: a potential eukaryotic reverse gyrase. Mol. Cell Biol. 14, 8391–8398. (doi:10.1128/mcb.14.12.8391-8398.1994)

203. Suski C, Marians KJ. 2008 Resolution of converging replication forks by RecQ and topoisomerase III. Mol. Cell 30, 779–789. (doi:10.1016/j.molcel.2008.04.020)

204. Croteau DL et al. 2012 RECQL4 localizes to mitochondria and preserves mitochondrial DNA integrity. Aging Cell 11, 436–466. (doi:10.1111/j.1474-9726.2012.00803.x)

205. De S et al. 2012 RECQL4 is essential for the transport of p53 to mitochondria in normal human cells in the absence of exogenous stress. J. Cell Sci. 125, 2509–2522. (doi:10.1242/jcs.101501)

206. Chi Z et al. 2012 RecQL4 cytoplasmic localization: implications in mitochondrial DNA oxidative damage repair. Int. J. Biochem. Cell Biol. 44, 1942–1951. (doi:10.1016/j.biocel.2012.07.016)

207. Viscomi C, Zeviani M. 2017 mtDNA-maintenance defects: syndromes and genes. J. Inherit Metab. Dis. 40, 587–599. (doi:10.1007/s10545-017-0027-5)

208. Martin CA et al. 2018 Mutations in TOP3A cause a Bloom syndrome-like disorder. Am. J. Hum. Genet. 103, 221–231. (doi:10.1016/j.ajhg.2018.07.001)

209. Jiang W, Jia N, Guo C, Wen J, Wu L, Ogi T, Zhang H. 2021 Predominant cellular mitochondrial dysfunction in the TOP3A gene-caused Bloom syndrome-like disorder. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166106. (doi:10.1016/j.bbadis.2021.166106)

210. Zhang H, Seol Y, Agama K, Neuman KC, Pommier Y. 2017 Distribution bias and biochemical characterization of TOP1MT single nucleotide variants. Sci. Rep. 7, 8614. (doi:10.1038/s41598-017-09258-2)

211. Tevey KM, Rowe TC, Yang L, Halligan BD, Liu LE. 1984 Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226, 466–468. (doi:10.1126/science.6053249)

212. Henriksen PA. 2018 Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart 104, 971–977. (doi:10.1136/heartjnl-2017-312103)

213. Stephenson AL, Wu W, Gortes D, Rochon PA. 2013 Tendon injury and fluoroquinolone use: a systematic review. Drug Saf. 36, 709–721. (doi:10.1007/s40264-013-0089-8)